• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Newsletters » The Carlat Addiction Treatment Report
carlat-addiction-header.png

The Carlat Addiction Treatment Report

Dual Diagnosis in Addiction Medicine (May/June) | 2019

View Archived Issues

CME Post-Test - Dual Diagnosis in Addiction Medicine, CATR, May/June 2019

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

Managing Substance-Related Agitation

In emergency departments, psychiatrists are often consulted on patients presenting with agitation. In many cases, these patients are under the influence of substances—either from intoxication or withdrawal. Read More

Treating Co-Occurring Psychiatric Disorders

Just about any psychiatric disorder has a higher rate of addiction comorbidity than in the general population. The rates are even higher in treatment settings—more than 50% of people in addiction treatment settings will have a co-occurring psychiatric problem, and more than 50% in psychiatric settings will typically have a co-occurring Substance Use Disorder. Read More

Cognitive Behavioral Therapy for Substance Use Disorders

Here’s the basic framework of Cognitive Behavioral Therapy (CBT), how it can be applied to Substance Use Disorders, and ways to incorporate parts of CBT into your daily addiction treatment practice. Read More

Co-Occurring Addiction and PTSD

Individuals who have PTSD have a high risk of developing other disorders, including substance use disorders (SUDs). Studies have shown that both in the veteran and non-veteran populations, these numbers are high. Read More

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone? Read More

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade. Read More

Learning Objectives, Dual Diagnosis in Addiction Medicine, CATR, May/June 2019

After reading these articles, you should be able to… Read More
SUBSCRIBE NOW
Editor-in-Chief
NCapurso.png
Noah Capurso, MD, MHS,

Dr. Capurso is an assistant professor of psychiatry and Director of Didactic Education at the Yale University School of Medicine. He practices clinically at the West Haven Veterans Administration Hospital. He attended medical school at Yale, where he received his MD, and where he conducted research in the Department of Biomedical Engineering. He stayed at Yale for residency and addiction psychiatry fellowship training. As a clinician, Dr. Capurso is the medical director of the VA’s Detoxification & Addiction Stabilization Service and the Psychosocial Residential Rehabilitation Program.

Full Editorial Information
Featured Book
  • PB4e_Cover2.png

    Psychiatry Practice Boosters, Fourth Edition (2023)

    Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.